8-K: Neogen Raises FY26 Outlook Amid Core Growth, Profitability Gains

Neogen Corporation reported second-quarter fiscal 2026 results, showing a 2.8% revenue decrease year-over-year but a 2.9% core revenue increase, and raised its full-year 2026 revenue and Adjusted EBITDA guidance.

Summary

• Q2 FY2026 revenue was $224.7 million, a decrease of 2.8% compared to $231.3 million in the prior year.
• Core revenue, excluding foreign currency translation, divestitures, and discontinued product lines, increased by 2.9% year-over-year.
• Net loss for the second quarter was $15.9 million, or $(0.07) per diluted share, a significant improvement from a net loss of $456.3 million in the prior-year period due to a non-recurring goodwill impairment charge.
• Adjusted Net Income for the second quarter was $22.6 million, or $0.10 per diluted share, compared to $24.4 million, or $0.11 per diluted share, in the prior-year period.
• Gross margin was 47.5% in Q2 FY2026, down from 49.0% in the same quarter a year ago.
• Adjusted EBITDA was $48.7 million, representing an Adjusted EBITDA Margin of 21.7%, compared to $51.4 million and a margin of 22.2% in the prior-year period.
• The Food Safety segment's revenue increased by 0.8% to $165.6 million, with 4.1% core revenue growth.
• The Animal Safety segment's revenue decreased by 11.8% to $59.1 million, with 0.1% core revenue growth.
• The company is raising its full-year fiscal 2026 outlook, with anticipated revenue in the range of $845 million to $855 million and Adjusted EBITDA expected to be approximately $175 million.
• Capital expenditures continue to be expected to total approximately $50 million for FY2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While total revenue and Adjusted Net Income saw year-over-year declines, core revenue growth was positive, and the company demonstrated significant sequential improvement in profitability. The decision to raise full-year guidance for both revenue and Adjusted EBITDA indicates management's confidence in future performance and strategic initiatives, outweighing the current mixed results.

Positives

• Core revenue increased by 2.9% year-over-year, demonstrating underlying business strength.
• Achieved significant sequential improvement in core revenue growth and profitability in the second quarter.
• Net loss of $15.9 million is a substantial improvement from the prior year's $456.3 million loss, which included a non-cash goodwill impairment charge.
• Adjusted EBITDA margin increased 470 basis points sequentially.
• The Petrifilm manufacturing transition remains on track, indicating successful integration efforts.
• Raised full-year fiscal 2026 revenue guidance to a range of $845 million to $855 million.
• Raised full-year fiscal 2026 Adjusted EBITDA guidance to approximately $175 million.
• Strengthened the leadership team with key senior commercial hires to accelerate strategic transition.
• Food Safety segment showed robust 4.1% core revenue growth, driven by Indicator Testing, Culture Media, sample collection products, and Petrifilm.
• Global Genomics business achieved mid-single-digit core revenue growth, led by bovine and other markets.

Negatives

• Total revenue decreased by 2.8% year-over-year to $224.7 million.
• Adjusted Net Income declined to $22.6 million from $24.4 million in the prior-year period, primarily due to lower operating income.
• Gross margin decreased to 47.5% from 49.0% in the prior year, primarily due to tariff costs, inventory write-offs, and a negative product mix.
• Adjusted EBITDA decreased to $48.7 million from $51.4 million in the prior-year period.
• The Animal Safety segment revenue decreased by 11.8% year-over-year, with lower sales in Veterinary Instruments & Disposables (needles and syringes) and Life Sciences (timing of substrate purchases).
• Experienced a decline in the companion animal market within the Genomics business.
• Divestitures and discontinued product lines represented a 6.6% negative impact on total revenue.

Risks

• Delays, costs, and operational challenges in continuing the integration of the former 3M Food Safety business.
• Ability to successfully implement transformation initiatives and possible disruptions to the business as a result of those initiatives.
• Changes to U.S. and international trade policies, including new or increased tariffs and changing import and export regulations.
• Global and national economic conditions, including those resulting from heightened inflation, foreign currency exchange rate fluctuations, and similar factors.
• The strength of internal controls and ability to successfully remediate material weaknesses in internal control over financial reporting.
• The outcome of pending litigation and/or governmental audits or investigations.

Future Outlook

Neogen is raising its full-year fiscal 2026 outlook, anticipating revenue in the range of $845 million to $855 million and Adjusted EBITDA of approximately $175 million. Capital expenditures are expected to remain at approximately $50 million.

Management Comments

• "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic transformation with early work focused on stabilizing and strengthening our core business."
• "While it is early in the process, and our industry is currently seeing macro headwinds, our team drove significant sequential improvement in core revenue growth and profitability in the second quarter."
• "As we look to the second half of the fiscal year, we remain highly focused on the integration of Petrifilm and optimization of sample collection manufacturing, as well as enhancing our solutions-based selling approach and implementing a continuous review of resource allocation across the enterprise."
• "To accelerate this transition, we have recently strengthened our leadership team with world-class talent, including key additions to our commercial organization."
• "These strategic hires will further align our focus on disciplined operational execution with our core objectives of reigniting revenue growth, improving profitability and delivering shareholder value."

Industry Context

The company acknowledges current macro headwinds impacting its industry. Despite these challenges, Neogen is focusing on strategic transformation, integration of key assets like Petrifilm, and optimizing manufacturing, suggesting a proactive approach to market conditions.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through reignited revenue growth and improved profitability, as indicated by raised guidance.
• Employees: Restructuring costs mentioned in non-GAAP adjustments suggest potential impact from headcount reductions.
• Customers: Focus on enhancing solutions-based selling approach aims to improve customer experience and value.

Next Steps

• Continue the integration of Petrifilm.
• Optimize sample collection manufacturing.
• Enhance solutions-based selling approach.
• Implement a continuous review of resource allocation across the enterprise.
• Focus on disciplined operational execution to reignite revenue growth, improve profitability, and deliver shareholder value.

Key Dates

Recommendation

Neogen's Q2 FY2026 results present a mixed picture with a year-over-year revenue decline but positive core growth and significant sequential improvement in profitability. The raised full-year guidance for both revenue and Adjusted EBITDA is a strong positive signal, indicating management's confidence in their strategic transformation and integration efforts, particularly with Petrifilm. However, the overall revenue decline and gross margin pressure suggest ongoing challenges. The company is in the early phases of a strategic transformation, and while early signs are promising, it's prudent to observe the sustained execution of these initiatives. Therefore, a 'hold' recommendation is appropriate, allowing investors to monitor the progress of the strategic transformation and its impact on financial performance in the coming quarters before making a more definitive move.

Keywords

Neogen, NEOG, Food Safety, Animal Safety, Genomics, Petrifilm, Q2 2026 Earnings, Financial Results, SEC Filing, Biosecurity, Indicator Testing, Culture Media, Pathogen Detection, Natural Toxins, Allergens, Veterinary Instruments, Biotech, Diagnostics